Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06450444 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The RECLAIM Study.

Study acronym: RECLAIM
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 11 sitesv11
  2. Site details revised at 5 of 11 sitesv10
  3. Enrollment target: 62 to 110 Primary completion date: Apr 1, 2026 to Apr 1, 2027 · Study sites: 8 to 11 · Completion date: Feb 1, 2028 to Jan 31, 2029 · 2 morev9 Show 5 more changesShow less
    • Primary completion date: Apr 1, 2026 to Apr 1, 2027
    • Study sites: 8 to 11
    • Completion date: Feb 1, 2028 to Jan 31, 2029
    • Eligibility criteria expanded, about 7 words
    • Study arms: 2 to 4

    See this version in full on ClinicalTrials.gov ↗

  4. Site details revised at 2 of 8 sitesv8
  5. Primary completion date: Oct 1, 2025 to Apr 1, 2026 Study sites: 9 to 8 · Completion date: Feb 1, 2027 to Feb 1, 2028v7 Show 2 more changesShow less
    • Study sites: 9 to 8
    • Completion date: Feb 1, 2027 to Feb 1, 2028
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 3 of 9 sitesv6
  2. Study sites: 7 to 9v5
  3. Site contacts updated at 3 of 7 sitesv4
  4. Study sites: 6 to 7v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 2 to 6 · Study title shortened, about 11 wordsv2 Show 2 more changesShow less
    • Study sites: 2 to 6
    • Study title shortened, about 11 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and performance, including clinical benefit, of the PRIMUS System for the treatment of Resistant Migraine.
Trial Details
NCT Number NCT06450444
Lead Sponsor Salvia BioElectronics
Conditions Chronic Migraine, High Frequency Episodic Migraine
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov